Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 3—March 2012

CME ACTIVITY - Research

Community-associated Clostridium difficile Infections, Monroe County, New York, USA

Ghinwa DumyatiComments to Author , Vanessa Stevens, George E. Hannett, Angela D. Thompson, Cherie Long, Duncan MacCannell, and Brandi Limbago
Author affiliations: University of Rochester, Rochester, New York, USA (G. Dumyati, V. Stevens); State University of New York at Buffalo, Buffalo, New York, USA (V. Stevens); New York State Department of Health, Albany, New York, USA (G.E. Hannett); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.D. Thompson, C. Long, D. MacCannell, B. Limbago)

Main Article

Table 6

Antimicrobial drug MICs for NAP 1/toxinotype III strains and other strains from case-patients with CDI, Monroe County, New York, USA, March 1–August 31, 2008*

Drug NAP1/toxinotype III, μg/mL
Other strains, μg/mL
MIC50 MIC90 Range MIC50 MIC90 Range
Clindamycin <2 >32 <2 to>32 <2 >32 <2 to >32
Levofloxacin >32 >32 <2 to >32 4 >32 <2 to >32
Moxifloxacin 16 >32 <2 to >32 <2 32 <2 to >32
Metronizadole 2 4 <0.5 to 4 <0.5 2 <0.5 to 2
Vancomycin 1 2 <0.5 to 2 1 2 <0.5 to 2

*NAP, North American pulsed-field; CDI, Clostridium difficile infection. Clinical and Laboratory Standards Institute interpretive criteria (sensitive/ intermediate/resistant): clindamycin: <2/4/>8 μg/mL; levofloxacin: not available; moxifloxacin: <2/4/>8 μg/mL; metronidazole: <8/16/>32 μg/mL; vancomycin: not available.

Main Article

TOP